| Safety and efficacy of propranolol for treatment of familial cerebral cavernous malformations (Treat_CCM): a randomised, open-label, blinded-endpoint, phase 2 pilot trial S Lanfranconi, E Scola, JMTA Meessen, R Pallini, GA Bertani, ... The Lancet Neurology 22 (1), 35-44, 2023 | 29 | 2023 |
| Coffee, atrial fibrillation, and circulating ceramides in patients with chronic heart failure C Signori, JMTA Meessen, R Laaksonen, AP Maggioni, D Novelli, ... Journal of Agricultural and Food Chemistry 69 (38), 11236-11245, 2021 | 7 | 2021 |
| Amplitude Spectrum Area of ventricular fibrillation to guide defibrillation: a small open-label, pseudo-randomized controlled multicenter trial L Ruggeri, F Fumagalli, F Bernasconi, F Semeraro, JMTA Meessen, ... EBioMedicine 90, 2023 | 6 | 2023 |
| Brain tumours in the time of COVID-19: An online survey on patients’ disease experience in one Italian region G Abete-Fornara, F Mameli, F Ruggiero, J Meessen, A Blanda, ... Frontiers in Oncology 13, 1002895, 2023 | 6 | 2023 |
| Circulating biomarkers in familial cerebral cavernous malformation F Lazzaroni, JMTA Meessen, Y Sun, S Lanfranconi, E Scola, ... EBioMedicine 99, 2024 | 1 | 2024 |
| Effects of hyperoxemia in patients with sepsis–a post-hoc analysis of a multicentre randomized clinical trial G Catalisano, M Ippolito, A Blanda, J Meessen, A Giarratano, N Todesco, ... Pulmonology, 2023 | 1 | 2023 |
| Patient-reported outcome measures in patients with familial cerebral cavernous malformations: results from the Treat_CCM trial JMTA Meessen, G Abete-Fornara, B Zarino, M Castori, L Tassi, ... Frontiers in Neurology 15, 1338941, 2024 | | 2024 |
